| Title |
Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date
|
|---|---|
| Published in |
Pediatric Drugs, March 2013
|
| DOI | 10.1007/s40272-013-0021-9 |
| Pubmed ID | |
| Authors |
Shahrad Rod Rassekh, Colin J. D. Ross, Bruce C. Carleton, Michael R. Hayden |
| Abstract |
Over the last few decades, cure rates for pediatric cancer have increased dramatically, and now over 80 % of children with cancer are cured of their disease. This improvement in cure has come with a significant cost, with many children suffering irreversible, life-threatening, or long-lasting toxicities due to the medications required during their treatment. In the last 2 decades, major technological advances in genomics and the mapping of the human genome have made it possible to identify genetic differences between children in order to investigate differing responses to cancer therapy and to help explain why children treated with the same medications can have different outcomes. The emerging field of pharmacogenomics has had many important findings in pediatric cancer. The focus of this review is drug toxicity in pediatric cancer and the use of pharmacogenomics to reduce these adverse drug reactions, with a specific focus on thiopurines, methotrexate, cisplatin, vincristine and anthracyclines. Future areas of research and the need for international collaboration are discussed. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 33% |
| Spain | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 33% |
| Members of the public | 1 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Unknown | 66 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 16% |
| Researcher | 10 | 15% |
| Student > Ph. D. Student | 8 | 12% |
| Student > Bachelor | 6 | 9% |
| Professor > Associate Professor | 6 | 9% |
| Other | 17 | 25% |
| Unknown | 9 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 12% |
| Nursing and Health Professions | 8 | 12% |
| Agricultural and Biological Sciences | 6 | 9% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Other | 11 | 16% |
| Unknown | 12 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2013.
All research outputs
#14,165,787
of 22,703,044 outputs
Outputs from Pediatric Drugs
#365
of 548 outputs
Outputs of similar age
#112,860
of 197,767 outputs
Outputs of similar age from Pediatric Drugs
#11
of 14 outputs
Altmetric has tracked 22,703,044 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 548 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,767 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.